drugset
drugset / Trial / NCT06429098

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

NCT06429098 ↗

Phase 2 Recruiting 40 enrolled The First Affiliated Hospital of Soochow University
NaSingle-groupOpen-labelTreatment

Summary

This investigator-initiated, single-arm, phase II trial is aimed to evaluate the efficacy and safety of a venetoclax-based, anthracycline-free regimen in patients with newly diagnosed CBFβ::MYH11-positive acute myeloid leukemia.

Timeline

Start
2024-01-01
Primary completion
2027-06-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified — Subcutaneous
Subject Cytarabine Small molecule — Intravenous
Subject Decitabine Small molecule — Intravenous
Subject Venetoclax Small molecule 400 mg Oral

Indications

acute myeloid leukemia